Cargando…
Iminosugar-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Potential Anti-Pancreatic Cancer Agents
The nicotinamide phosphoribosyltransferase (NAMPT) is considered a very promising therapeutic target because it is overexpressed in pancreatic cancer. Although many inhibitors have been prepared and tested, clinical trials have shown that NAMPT inhibition may result in severe haematological toxicity...
Autores principales: | Conforti, Irene, Benzi, Andrea, Caffa, Irene, Bruzzone, Santina, Nencioni, Alessio, Marra, Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222582/ https://www.ncbi.nlm.nih.gov/pubmed/37242714 http://dx.doi.org/10.3390/pharmaceutics15051472 |
Ejemplares similares
-
Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies
por: Biniecka, Paulina, et al.
Publicado: (2023) -
Association of Nicotinamide Phosphoribosyltransferase (NAMPT) Gene Polymorphisms and of Serum NAMPT Levels with Dilated Cardiomyopathy in a Chinese Population
por: Dou, Qingyu, et al.
Publicado: (2015) -
Extracellular nicotinamide phosphoribosyltransferase: role in disease pathophysiology and as a biomarker
por: Semerena, Elise, et al.
Publicado: (2023) -
Metabolomics Analysis of Metabolic Effects of Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibition on Human Cancer Cells
por: Tolstikov, Vladimir, et al.
Publicado: (2014) -
Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy
por: LoCoco, Peter M, et al.
Publicado: (2017)